ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer

Cancer Letters

Volumn 81, Issue 2, 1994, Pages 137-144

  Borg, Åke ^a   Baldetorp, Bo ^a   Fernö, Mårten ^a   Killander, Dick ^a   Olsson, Håkan ^a   Ryden, Stefan ^b   Sigurdsson, Helgi ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b Department of Surgery Ängelholm Hospital ^*  (Sweden)

Author keywords

Adjuvant tamoxifen; Breast cancer; ERBB2; Gene amplification; HER 2 neu; Therapy resistance

Indexed keywords

CYCLOPHOSPHAMIDE; ESTROGEN RECEPTOR; GROWTH FACTOR RECEPTOR; TAMOXIFEN;

ARTICLE; BREAST CANCER; FEMALE; GENE ACTIVATION; GENE EXPRESSION; HUMAN; LYMPHOMA; MAJOR CLINICAL STUDY; ONCOGENE; PRIORITY JOURNAL; RADIOTHERAPY; RECEPTOR UPREGULATION; THERAPY RESISTANCE;

BREAST NEOPLASMS; DRUG RESISTANCE; FEMALE; GENE AMPLIFICATION; HUMAN; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SUPPORT, NON-U.S. GOV'T; TAMOXIFEN;

EID: 0028360192     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/0304-3835(94)90194-5     Document Type: Article

References (26)

1. Tamoxifen up-regulates c-erbB-2 expression in oestrogen-responsive breast cancer cells in vitro
2. A ligand for the erbB-2 oncogene product (gp30) induces differentiation of human breast cancer cells
3. Statistical evaluations of cell kinetic data from DNA flow cytometry (FCM) by the EM algorithm
4. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu
5. HER-2/neu amplification predicts poor prognosis in node-positive breast cancer
6. ERBB2 amplification in breast cancer with a high rate of proliferation
7. Steroid receptors and other prognostic factors in primary breast cancer
8. Estrogenic regulation of growth and polypeptide growth factor secretion in human breast carcinomas
9. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy
10. Estrogen receptor mutations in breast cancer
11. Prognostic importance of c-erbB-2 expression in breast cancer
12. Identification of heregulin, a specific activator of p185-ERBB2
13. Towards a molecular basis for tamoxifen resistance in breast cancer
14. A current view of tamoxifen for the treatment and prevention of breast cancer
15. Amplification of a novel v-erbB-related gene in a human mammary carcinoma
16. 17-Beta-estradiol mimics ligand activity of the c-erbB2 protooncogene product
17. Improved method for assay of estradiol and progesterone receptors with special reference to breast cancer
18. Isolation of the neu/HER-2 stimulatory ligand: a 44 kd glycoprotein that induces differentiation of mammary tumour cells
19. c-erbB-2 oncogene as a prognostic marker in breast cancer
20. Heregulin induces tyrosine phosphorylation of [frsol|HER4/p180-erbB4
21. The case for clinical trials of tamoxifen for prevention of breast cancer
22. Hormonal modulation of HER-2/neu protooncogene messenger ribonucleic acid and p185 protein expression in human breast cancer cell lines
23. Transcriptional repression of the neu protooncogene by estrogen stimulated estrogen receptor
24. Role of estrogen receptor variants in the development of hormone resistance in breast cancer
25. Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer
26. Estrogen suppression of ERBB2 expression is associated with increased growth rate of ZR75-1 human breast cancer cells in vitro and in nude mice